| 
  ||||
|  
       Clinical TrialsMedicare | Clinical TrialsPrivate Insurance | Medicare Payment FDA | Cancer Research | Stem Cell Research | Privacy | Other  | 
  ||||
|  
       | 
    ||||
|  
      
      
       SENIOR 
        GROUPS JOIN CLC IN LETTER TO CONGRESS ENDORSING November 27, 2001 Dear Senator/Representative: The undersigned organizations, representing seniors, cancer patients, providers, and health care organizations, applaud the united and bipartisan response to the events of September 11. We join the rest of the nation in offering support to Congress and the Administration at this time of grief and recovery. We understand that the energies of Congress must be directed to prompt action on measures to aid in the nation's healing from the recent terrorist attacks and that the Congressional agenda may be abbreviated to allow efforts to concentrate on recovery measures. However, if Congress chooses to consider a Medicare amendments package this year, we urge that you include a provision to expand current Medicare Part B coverage of anti-cancer drugs to oral anti-cancer agents for which there is no intravenous equivalent. House and Senate versions of the Access to Cancer Therapies Act (H.R. 1624 and S. 913), authorizing Medicare coverage of oral anti-cancer agents, enjoy broad bipartisan support and represent important incremental reform. Medicare already covers the cost of most anti-cancer drugs because those drugs are administered by injection by providers. Since 1993, oral anti-cancer drugs with an injectable equivalent have also been covered by Medicare. Unfortunately, many of the most important oral anti-cancer agents would not be eligible for Medicare coverage because they have no intravenous equivalent. To guarantee that seniors have access to new, more effective anti-cancer drugs, Medicare should pay for them. In the past, Medicare beneficiaries have been able to depend on the program for quality cancer care, and expanding the current system of coverage to include oral anti-cancer drugs will ensure that beneficiaries still have access to good cancer care. We believe that this approach would be a modest improvement to Medicare that Congress should consider this fall. During the last year, you have heard from cancer advocates regarding this legislation, and they are now joined by a number of senior organizations in promoting this legislation to ensure that beneficiaries with cancer have access to all cancer treatment options. This is a responsible approach to enhancing Medicare benefits, and we urge you to consider it as a step toward more comprehensive reform in the future. We stand ready to provide you with additional information about promising new oral anti-cancer therapies and about how the Access to Cancer Therapies Act will help beneficiaries. Sincerely, AFSCME Retiree Program Cancer Leadership Council
         
         Alliance for Lung Cancer Advocacy, Support and Education
         American Cancer Society
         Association of American Cancer Institutes
         Cancer Care, Inc.
         Coalition of National Cancer Cooperative Groups, Inc.
         Colorectal Cancer Network
         Kidney Cancer Association
         The Leukemia & Lymphoma Society
         Lymphoma Research Foundation
         Multiple Myeloma Research Foundation
         National Coalition for Cancer Survivorship
         National Patient Advocate Foundation
         National Prostate Cancer Coalition
         Oncology Nursing Society
         Ovarian Cancer National Alliance
         Pancreatic Cancer Action Network
         Susan G. Komen Breast Cancer Foundation
         US TOO! International, Inc.
         The Wellness Community
         Y-ME National Breast Cancer Organization
      Contact Information: Ellen Stovall, Executive 
        Directo   Back to Medicare Payment Index 
 About 
        CLC  |  What's New  |  
        Policy Issues  |  
        Participants' Login Copyright 
        © 2001-2002 Cancer Leadership Council. All rights reserved.  | 
    ||||